Validation of a Hand-Held Point-of-Care Device to Measure Breath Hydrogen and Its Utility in Detecting Response to Antibiotic Treatment.
Digital health
Personal breath test device
Postprandial breath hydrogen
Remote patient monitoring
Remote testing
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
10 Aug 2024
10 Aug 2024
Historique:
received:
19
03
2024
accepted:
31
07
2024
medline:
11
8
2024
pubmed:
11
8
2024
entrez:
10
8
2024
Statut:
aheadofprint
Résumé
Breath testing for small intestinal bacterial overgrowth (SIBO) is typically performed using clinic-based equipment or single-use test kits. This study aimed to evaluate the utility of a portable, point-of-care breath analysis device (AIRE®, FoodMarble) in patients suspected to have SIBO. A technical assessment including a comparison to existing mail-in kits was first performed. Then, postprandial breath hydrogen levels of patients before and after antibiotic treatment were gathered and compared to levels seen in a healthy cohort. For the comparison, 50 patients suspected of having SIBO were provided with an AIRE device and performed concurrent LHBTs at-home with a mail-in breath test kit. For the postprandial analysis, twenty-four patients with chronic GI symptoms measured their postprandial hydrogen for 7 days prior to antibiotic treatment and for 7 days after treatment. 10 healthy controls also measured their postprandial hydrogen for 7 days. Substantial agreement was demonstrated between AIRE and the mail-in kits for the performance of lactulose hydrogen breath tests (κ = 0.8). Prior to treatment, patients had significantly greater daily postprandial hydrogen than healthy controls (p < 0.001). The mean postprandial hydrogen of patients reduced significantly after treatment (p < 0.001). Measuring postprandial hydrogen shows potential as a means of differentiating patients with chronic GI symptoms from healthy controls and may be useful in monitoring patients before, during, and after treatment. Future studies could help determine if pre-treatment breath gas levels are predictive of response to antibiotic treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Breath testing for small intestinal bacterial overgrowth (SIBO) is typically performed using clinic-based equipment or single-use test kits.
AIMS
OBJECTIVE
This study aimed to evaluate the utility of a portable, point-of-care breath analysis device (AIRE®, FoodMarble) in patients suspected to have SIBO. A technical assessment including a comparison to existing mail-in kits was first performed. Then, postprandial breath hydrogen levels of patients before and after antibiotic treatment were gathered and compared to levels seen in a healthy cohort.
METHODS
METHODS
For the comparison, 50 patients suspected of having SIBO were provided with an AIRE device and performed concurrent LHBTs at-home with a mail-in breath test kit. For the postprandial analysis, twenty-four patients with chronic GI symptoms measured their postprandial hydrogen for 7 days prior to antibiotic treatment and for 7 days after treatment. 10 healthy controls also measured their postprandial hydrogen for 7 days.
RESULTS
RESULTS
Substantial agreement was demonstrated between AIRE and the mail-in kits for the performance of lactulose hydrogen breath tests (κ = 0.8). Prior to treatment, patients had significantly greater daily postprandial hydrogen than healthy controls (p < 0.001). The mean postprandial hydrogen of patients reduced significantly after treatment (p < 0.001).
CONCLUSIONS
CONCLUSIONS
Measuring postprandial hydrogen shows potential as a means of differentiating patients with chronic GI symptoms from healthy controls and may be useful in monitoring patients before, during, and after treatment. Future studies could help determine if pre-treatment breath gas levels are predictive of response to antibiotic treatment.
Identifiants
pubmed: 39127844
doi: 10.1007/s10620-024-08583-7
pii: 10.1007/s10620-024-08583-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Black CJ, Drossman DA, Talley NJ, Ruddy J, Ford AC. Functional gastrointestinal disorders: advances in understanding and management. Lancet (London, England). 2020;396:1664–1674.
doi: 10.1016/S0140-6736(20)32115-2
pubmed: 33049221
Sperber AD, Bangdiwala SI, Drossman DA et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160:99-114.e3.
doi: 10.1053/j.gastro.2020.04.014
pubmed: 32294476
Carco C, Young W, Gearry RB, Talley NJ, McNabb WC, Roy NC. Increasing evidence that irritable bowel syndrome and functional gastrointestinal disorders have a microbial pathogenesis. Front Cell Infect Microbiol. 2020;10:468.
doi: 10.3389/fcimb.2020.00468
pubmed: 33014892
pmcid: 7509092
Wei L, Singh R, Ro S, Ghoshal UC. Gut microbiota dysbiosis in functional gastrointestinal disorders: underpinning the symptoms and pathophysiology. JGH Open. 2021;5:976–987.
doi: 10.1002/jgh3.12528
pubmed: 34584964
pmcid: 8454481
Jones RB, Zhu X, Moan E et al. Inter-niche and inter-individual variation in gut microbial community assessment using stool, rectal swab, and mucosal samples. Sci Rep. 2018;8:4139.
doi: 10.1038/s41598-018-22408-4
pubmed: 29515151
pmcid: 5841359
Saffouri GB, Shields-Cutler RR, Chen J et al. Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nat Commun. 2019;10:2012.
doi: 10.1038/s41467-019-09964-7
pubmed: 31043597
pmcid: 6494866
Wang L, Alammar N, Singh R et al. Gut microbial dysbiosis in the irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. J Acad Nutr Diet. 2020;120:565–586.
doi: 10.1016/j.jand.2019.05.015
pubmed: 31473156
Tap J, Störsrud S, Le Nevé B et al. Diet and gut microbiome interactions of relevance for symptoms in irritable bowel syndrome. Microbiome. 2021;9:74.
doi: 10.1186/s40168-021-01018-9
pubmed: 33771219
pmcid: 8004395
Kumar S, Misra A, Ghoshal UC. Patients with irritable bowel syndrome exhale more hydrogen than healthy subjects in fasting state. J Neurogastroenterol Motil. 2010;16:299–305.
doi: 10.5056/jnm.2010.16.3.299
pubmed: 20680169
pmcid: 2912123
Ong DK, Mitchell SB, Barrett JS et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol. 2010;25:1366–1373.
doi: 10.1111/j.1440-1746.2010.06370.x
pubmed: 20659225
Fodor AA, Pimentel M, Chey WD et al. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Gut Microbes. 2019;10:22–33.
doi: 10.1080/19490976.2018.1460013
pubmed: 29708822
Soldi S, Vasileiadis S, Uggeri F et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol. 2015;8:309–325.
doi: 10.2147/CEG.S89999
pubmed: 26673000
pmcid: 4675645
Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008;53:169–174. https://doi.org/10.1007/s10620-007-9839-8
doi: 10.1007/s10620-007-9839-8
pubmed: 17520365
Moraru IG, Portincasa P, Moraru AG, Diculescu M, Dumitraşcu DL. Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study. Rom J Intern Med. 2013;51:143–147.
pubmed: 24620626
Bae S, Lee KJ, Kim YS, Kim KN. Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects. J Korean Med Sci.
Rezaie A, Buresi M, Lembo A et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol. 2017;112:775–784.
doi: 10.1038/ajg.2017.46
pubmed: 28323273
pmcid: 5418558
Buderer NM. Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity. Acad Emerg Med. 1996;3:895–900.
doi: 10.1111/j.1553-2712.1996.tb03538.x
pubmed: 8870764
Losurdo G, Leandro G, Ierardi E et al. Breath tests for the non-invasive diagnosis of small intestinal bacterial overgrowth: a systematic review with meta-analysis. J Neurogastroenterol Motil. 2020;26:16–28.
doi: 10.5056/jnm19113
pubmed: 31743632
pmcid: 6955189
Ghoshal UC, Nehra A, Mathur A, Rai S. A meta-analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome. J Gastroenterol Hepatol. 2020;35:922–931.
doi: 10.1111/jgh.14938
pubmed: 31750966
King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet. 1998;352:1187–1189.
doi: 10.1016/S0140-6736(98)02146-1
pubmed: 9777836
Di Stefano M, Strocchi A, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther. 2000;14:1001–1008.
doi: 10.1046/j.1365-2036.2000.00808.x
pubmed: 10930893
Koide A, Yamaguchi T, Odaka T et al. Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome. Am J Gastroenterol. 2000;95:1735–1741.
doi: 10.1111/j.1572-0241.2000.02189.x
pubmed: 10925977
Youn YH, Park JS, Jahng JH et al. Relationships among the lactulose breath test, intestinal gas volume, and gastrointestinal symptoms in patients with irritable bowel syndrome. Dig Dis Sci. 2011;56:2059–2066. https://doi.org/10.1007/s10620-011-1569-2
doi: 10.1007/s10620-011-1569-2
pubmed: 21240630
Ringel-Kulka T, Benson AK, Carroll IM, Kim J, Legge RM, Ringel Y. Molecular characterization of the intestinal microbiota in patients with and without abdominal bloating. Am J Physiol Gastrointest Liver Physiol. 2016;310:G417–G426.
doi: 10.1152/ajpgi.00044.2015
pubmed: 26702134
Kassinen A, Krogius-Kurikka L, Mäkivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24–33.
doi: 10.1053/j.gastro.2007.04.005
pubmed: 17631127
Leite G, Morales W, Weitsman S et al. The duodenal microbiome is altered in small intestinal bacterial overgrowth. PLoS One. 2020;15:e0234906.
doi: 10.1371/journal.pone.0234906
pubmed: 32645011
pmcid: 7347122